T-Cell Co-Culture Potency Assays for Faster TIL Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TIL manufacturing and treatment processes are limited by length, cost, and sterility concerns, and there is a need for improved quality control methods to enhance the potency and functionality of T cells for cancer treatment, particularly for patients refractory to other therapies.
Innovation Solution
A method for assessing T cell potency through co-culture with target and negative control cells, evaluating marker expression and analyte secretion, and a manufacturing process involving closed system expansions with IL-2 and APCs to produce therapeutic TIL populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional TIL manufacturing processes are used, then T cell expansion is achieved, but the process length is excessive and costs are high
Solution Approach 1:
The patent applies preliminary action by pre-selecting and expanding specific T cell subsets (such as CD8+ TEM cells) before the main TIL expansion process. This preliminary enrichment of potent T cell populations allows for shorter overall manufacturing times while maintaining therapeutic efficacy, as these pre-selected cells have higher proliferative capacity and anti-tumor activity.
Solution Approach 2:
The patent employs parameter changes by modifying culture conditions including IL-2 concentration, cell density, and culture duration to optimize TIL expansion. By adjusting these parameters dynamically during different expansion phases, the process achieves faster growth rates and reduced manufacturing time while maintaining cell potency and functionality.
2Reliability
If traditional TIL manufacturing processes are used, then T cell expansion is achieved, but sterility concerns and quality control issues arise
Solution Approach 1:
The patent applies the taking out principle by extracting and isolating specific T cell subsets (CD8+ TEM, TCM cells) from the mixed TIL population through flow cytometry-based selection. This extraction of potent subsets allows for more controlled expansion with reduced risk of contaminating cell types, improving product consistency and quality while simplifying downstream processing and quality control.
Solution Approach 2:
The patent implements feedback mechanisms through potency assays that measure T cell functionality markers (such as cytokine production, proliferation capacity) at various expansion stages. This feedback allows real-time monitoring and adjustment of expansion conditions to ensure consistent product quality, reducing batch-to-batch variability and simplifying release criteria.
3Adaptability or versatility
If TIL therapy is used for refractory cancer patients, then treatment options are provided, but current processes are too limited and expensive
Solution Approach 1:
The patent applies segmentation by dividing the TIL manufacturing process into distinct modular phases: initial TIL generation, potent subset selection, targeted expansion, and quality assessment. This segmentation allows each module to be optimized independently and enables flexible scaling, making the therapy more accessible and adaptable to different patient needs and resource availability.
Data Source
AI summary
The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.